Navigation Links
Vivakor Announces Launch of VivaThermic Website and Highlights Distribution & Sales of Its VivaThermic Products in Japan Through Veritas Corporation

CORALVILLE, Iowa, Dec. 14 /PRNewswire-FirstCall/ -- Vivakor, Inc. (OTC Bulletin Board: VIVK) today announced the launch of its new website promoting its remarkable VivaThermic Vial at In addition to providing customers with the latest news and developments for its VivaThermic product line, Vivakor developed this site to be a valuable resource for its domestic and international customers, such as the highly respected Veritas Corporation of Tokyo, Japan, which signed an exclusive five year exclusive distribution agreement to distribute Vivakor's VivaThermic products in Japan. Under the terms of the Agreement, Veritas will have exclusive distribution rights to all Vivakor's VivaThermic Division products in Japan, including the recently released VivaThermic SUPER-150 and VivaThermic UTLRA-300 cryovials.

Mr. Shinsaku Iida, President of Veritas Corporation, stated: "As a leading distributor of a biotech products in Japan, including capital equipment, reagents, and kits to support research in the fields of genomics, proteomics, and metabolomics, we believe we are the perfect partner for Vivakor and their VivaThermic product line. In Japan, as in the rest of the world, there is a real need for better sample preparation methods that will allow for the safe, rapid, and reliable sample preservation from a variety of biomaterials. We are very impressed with new Ultra CryoVials, believe that it is the best system available for sample preservation, and believe that we will be very successful in placing the entire cryo-preservation system in the Japanese market as 21 century's gold standard."

Vivakor's CEO, Dr. Tannin Fuja, indicated that, "We are pleased to launch the VivaThermic website that will not only promote domestic distribution but assist our international distributors. We are also pleased to partner with the highly-respected Japanese corporation, Veritas, to distribute our superior VivaThermic products. The Japanese biotechnology industry is one of the leading participants in the global biotech market. Japan, with its family of industry leading biotechnology companies, continues to lead in this increasingly global market."

About Vivakor

Vivakor(TM) is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds that extend or improve life. More information can be found about Vivakor at

About Veritas Corporation

Veritas is a trusted distributor of cutting edge products from around the world to the Japanese life science community. Established in 1972, Veritas is well known for superior technical support and knowledgeable sales and marketing staff. In addition to Vivakor's VivaThermic products, Veritas represents prestigious suppliers from USA, Canada, Germany, England, Sweden, Italy, New Zealand, China, and India for life science products. Veritas specializes in cell biology (including stem cell biology), immunology, hematology and microbiology, as well as to sophisticated scientific instruments and niche services.


This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's products and their related market potential. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

    Vivakor Investor Relations
    c/o IME Advisors
    (888) 648-848

SOURCE Vivakor, Inc.

SOURCE Vivakor, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Vivakor Announces New Acquisition Strategy
2. Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customers Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders
3. Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer
4. ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
5. Boston Scientific Announces Pricing of $2 Billion of Senior Notes
6. Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy
7. RetireSafe Announces Intention to Key Vote Senator Dorgans Drug Importation Amendment (SA 2793)
8. Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign
9. Neogen Corporation Announces 2nd Quarter Results
10. China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009
11. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
Post Your Comments:
(Date:11/25/2015)... 25, 2015 ... the "Global Brain Monitoring Devices Market ... --> ) has announced the ... Devices Market 2015-2019" report to their ... ( ) has announced the addition ...
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... WOODBURY, N.Y. , Nov. 25, 2015  Linden ... access and optimizing treatment outcomes for patients suffering from ... its request for a Temporary Restraining Order (TRO) enjoining ... between the two companies. --> ... aggressively pursuing all of its legal options. ...
Breaking Medicine Technology:
(Date:11/27/2015)... , ... November 27, 2015 , ... ... an innovative online platform for mental health and wellness consultation, has collaborated with ... partnership will bridge the knowledge gap experienced by parents and bring advice from ...
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap and Dr. ... Tucker Bierbaum with Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial ... conditions present in similar ways and require time-critical intervention to avoid large area heart ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity ... have come together on Thanksgiving Day to share the things that they are ... the Serenity Point YouTube channel, patients displayed what they wrote on index cards, ...
(Date:11/26/2015)... ... November 26, 2015 , ... Somu Sivaramakrishnan announced ... franchise owner, Somu now offers travelers, value and care based Travel Services, including ... sales, as well as, cabin upgrades and special amenities such as, shore excursions, ...
(Date:11/26/2015)... ... , ... PRMA Plastic Surgery is updating their record books yet again with ... flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, says ... it’s an honor to have served all of these women.” , PRMA is one ...
Breaking Medicine News(10 mins):